share_log

Stem Analyst Ratings

Benzinga ·  Nov 3, 2023 08:30
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/03/2023 Guggenheim Downgrades Buy → Neutral
11/02/2023 15.26% Roth MKM $6 → $3.7 Maintains Neutral
11/01/2023 15.26% Roth MKM $6 → $3.7 Maintains Neutral
10/24/2023 55.76% Barclays $6 → $5 Maintains Equal-Weight
10/20/2023 55.76% Exane BNP Paribas → $5 Initiates Coverage On → Neutral
10/17/2023 118.07% Morgan Stanley $8 → $7 Maintains Equal-Weight
10/06/2023 24.61% Piper Sandler $5 → $4 Maintains Neutral
09/08/2023 429.6% Evercore ISI Group $11 → $17 Maintains Outperform
09/06/2023 149.22% Morgan Stanley $12 → $8 Downgrades Overweight → Equal-Weight
08/30/2023 86.92% Barclays → $6 Initiates Coverage On → Equal-Weight
07/20/2023 86.92% B of A Securities $5 → $6 Maintains Underperform
06/23/2023 86.92% Piper Sandler → $6 Initiates Coverage On → Neutral
06/14/2023 273.83% Morgan Stanley → $12 Reiterates → Overweight
06/06/2023 273.83% Janney Montgomery Scott → $12 Initiates Coverage On → Buy
05/24/2023 242.68% Evercore ISI Group → $11 Initiates Coverage On → Outperform
04/06/2023 195.95% UBS $18 → $9.5 Maintains Buy
04/06/2023 Wolfe Research Downgrades Outperform → Peer Perform
04/04/2023 55.76% B of A Securities $9 → $5 Downgrades Neutral → Underperform
04/03/2023 273.83% Morgan Stanley $15 → $12 Maintains Overweight
03/30/2023 273.83% Susquehanna $17 → $12 Maintains Positive
03/30/2023 273.83% Goldman Sachs $14 → $12 Maintains Buy
02/21/2023 336.14% Goldman Sachs $16 → $14 Maintains Buy
02/21/2023 523.05% Credit Suisse $24 → $20 Maintains Outperform
02/17/2023 429.6% Susquehanna $20 → $17 Maintains Positive
02/10/2023 242.68% B of A Securities → $11 Initiates Coverage On → Neutral
01/10/2023 367.29% Morgan Stanley → $15 Upgrades Equal-Weight → Overweight
12/20/2022 398.44% Goldman Sachs $18 → $16 Maintains Buy
10/25/2022 491.9% UBS → $19 Initiates Coverage On → Buy
09/29/2022 523.05% Cowen & Co. $22 → $20 Maintains Outperform
09/29/2022 554.21% Morgan Stanley $20 → $21 Maintains Equal-Weight
09/22/2022 585.36% Cowen & Co. → $22 Initiates Coverage On → Outperform
09/07/2022 647.66% Northland Capital Markets → $24 Initiates Coverage On → Outperform
08/18/2022 523.05% Morgan Stanley $13 → $20 Maintains Equal-Weight
03/23/2022 304.98% Morgan Stanley → $13 Initiates Coverage On → Equal-Weight
03/22/2022 398.44% Guggenheim → $16 Initiates Coverage On → Buy
11/22/2021 990.34% Wolfe Research → $35 Initiates Coverage On → Outperform
07/19/2021 990.34% Susquehanna → $35 Initiates Coverage On → Positive
06/29/2021 1395.33% Credit Suisse → $48 Initiates Coverage On → Outperform
05/24/2021 834.58% Goldman Sachs → $30 Initiates Coverage On → Buy

What is the target price for Stem (STEM)?

The latest price target for Stem (NYSE: STEM) was reported by Guggenheim on November 3, 2023. The analyst firm set a price target for $0.00 expecting STEM to fall to within 12 months (a possible -100.00% downside). 27 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Stem (STEM)?

The latest analyst rating for Stem (NYSE: STEM) was provided by Guggenheim, and Stem downgraded their neutral rating.

When is the next analyst rating going to be posted or updated for Stem (STEM)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Stem, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Stem was filed on November 3, 2023 so you should expect the next rating to be made available sometime around November 3, 2024.

Is the Analyst Rating Stem (STEM) correct?

While ratings are subjective and will change, the latest Stem (STEM) rating was a downgraded with a price target of $0.00 to $0.00. The current price Stem (STEM) is trading at is $3.21, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment